Full-Time
Engineer 3
Omnicell
1,001-5,000 employees
Medication management and pharmacy automation platform
No salary listed
Grove City, PA, USA
In Person
 Software Engineering (1) |
|---|
Get referred to Omnicell
See people who can refer or advise you
- Programming experience in one or more object-oriented languages.
- Programming experience for test automation using Playwright framework.
- Experience creating automation tests and using test frameworks for RESTful services.
- Experience creating automation tests and using test frameworks for Message queues.
- Experience creating automation tests and using test frameworks for Relational databases.
- Experience creating automation tests and using test frameworks for Web applications.
- Understanding of TDD, BDD, and data-driven test practices.
- Experience testing and validating on-prem as well as SaaS-based solutions.
- Ability to collaborate effectively and contribute positively to team culture.
- Ability to consistently put the customer first.
- Comfort working with AI copilots, test-generation tools, and AI-driven analysis utilities.
- Ability to craft precise prompts for AI agents to produce reliable test artifacts, test plans, defect summaries, and reports.
- AI-first mindset—viewing AI as a core accelerant to productivity, creativity, and test coverage.
- Bachelor’s degree in Engineering, Computer Science, Math, Physics or other Science/ Engineering field preferred; experience may be considered in lieu of Bachelor’s degree
- 5+ years hands-on experience in software development with degree
- Demonstrated software leadership experience in an agile environment
- Work as part of a team to design, develop, test, deploy, maintain, and improve software, including leveraging AI tools to accelerate each phase
- Deliver high‑quality software solutions using C#, .NET, MS SQL, and Microservices architecture, applying AI assistance where appropriate while maintaining engineering rigor
- Use AI systems to generate or refine code, tests, design artifacts, documentation, and troubleshooting strategies
- Collaborate with software quality engineers in all phases of testing, including using AI to generate, optimize, and validate test cases
- Collaborate with cross‑functional teams on documentation and training; use AI to accelerate documentation creation and knowledge sharing
- Conduct code reviews—including review of AI‑generated code—to ensure maintainability, security, performance, and compliance
- Create unit tests (including AI‑suggested tests) to ensure code quality throughout the application's lifecycle
- Understand how Omnicell solutions meet customer needs and how products are used across the continuum of care
- Grow and mentor other engineers in both traditional engineering practices and AI‑assisted workflows
- Demonstrate strong prompt‑engineering fundamentals: iterating on prompts, validating AI outputs, and selecting the right AI tool for the right task
- Advocate for and model an AI‑first engineering mindset, focusing on productivity, safety, and innovation
- M.S. in Computer Science, Computer Engineering or other engineering fields of study
- Healthcare or Medical Device software development experience
Omnicell provides medication management solutions and adherence tools for health systems and pharmacies, combining pharmacy automation devices with cloud-based software to automate dispensing, manage inventory, and support patient adherence. The products mix hardware and a cloud platform that coordinates dispensing, inventory control, and clinical data through dashboards and analytics. Compared with competitors, Omnicell emphasizes a cloud-first software approach with a clear path to software-as-a-service and a hybrid direct-plus-partner sales model for end-to-end pharmacy automation and data services. Its goal is to realize the Autonomous Pharmacy by using automation and intelligent services to improve pharmacy care and patient outcomes while building recurring revenue.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Mountain View, California
Founded
1992
Get referred to Omnicell
See people who can refer or advise you
Simplify's Take
What believers are saying
- Titan XT targets a $2.5 billion installed-base replacement opportunity.
- Recurring revenue is rising, with 2026 annual recurring revenue guided to $680–700 million.
- Mandoli's May 2026 hire strengthens specialty pharmacy and 340B expansion execution.
What critics are saying
- BD and other rivals can win hospital automation budgets through bundled contracts.
- Hospital capital freezes delay Titan XT shipments and software conversion timing.
- Tariffs add about $12 million of 2026 costs, pressuring hardware margins.
What makes Omnicell unique
- Omnicell combines medication automation, software, and services across hospitals and pharmacies.
- OmniSphere centralizes cloud-native pharmacy workflows and real-time inventory visibility.
- Specialty Pharmacy Services and 340B expand Omnicell beyond cabinet hardware.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Omnicell's analyst narrative centres on its Titan XT cabinet system and a potential hospital replacement cycle, though opinions diverge sharply on timing. The modelled fair value holds at $57.43 amid mixed price target revisions. BofA, Benchmark and KeyBanc have taken bullish stances, with KeyBanc upgrading to Overweight at $60, citing competitive wins and a cabinet refresh cycle. Conversely, Piper Sandler cut its target by $14, flagging execution and timing risks around the same Titan XT story. Omnicell issued Q1 2026 revenue guidance of $300 million to $310 million and full-year guidance of $1.215 billion to $1.255 billion. The company has launched Titan XT in the US, with international rollout expected later in 2026.
Omnicell, Inc. is transitioning from hardware-driven revenue to a software and services model, aiming to double revenue from $1.18 billion to $2.4 billion by 2031, according to a bullish thesis on Danny's Substack. The company is expanding through strategic acquisitions like ANiGENT and developing its "Autonomous Pharmacy" vision using AI and robotics. The healthcare automation firm benefits from high switching costs, over 900 patents and a large installed base. Recurring revenue is approaching 50% of total revenue, with margins expected to expand from low teens to mid-20s. Bulls believe the market currently undervalues Omnicell as a hardware vendor, creating potential for significant rerating as it shifts towards healthcare IT, with shares trading at $38.61 as of 18 February.
Omnicell, a provider of medication management automation and adherence tools for healthcare systems and pharmacies, reported third-quarter revenues of $310.6 million, up 10% year on year and exceeding analysts' expectations by 5%. The company also beat earnings per share estimates. "We are pleased with the strong financial performance delivered in the third quarter," said Randall Lipps, Omnicell's chairman, president and chief executive officer. The stock has risen 64% since reporting results and currently trades at $48.49. The healthcare technology for providers sector faces mixed conditions, with opportunities from AI-driven tools and government digitisation incentives offset by challenges including long sales cycles, slow adoption rates, and tightening hospital budgets. The four companies tracked in this sector reported satisfactory third-quarter results overall, though share prices have declined 5.3% on average since earnings.
This May, medication and supply management technology company Omnicell launched a new radio frequency identification (RFID)-enabled device to manage medications in the operating room.
Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.